Advertisement

Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms

      Abstract

      OBJECTIVE: Previous reports have suggested that disturbances in calcium regulation may underlie the pathophysiologic characteristics of premenstrual syndrome and that calcium supplementation may be an effective therapeutic approach. To evaluate the effect of calcium carbonate on the luteal and menstrual phases of the menstrual cycle in premenstrual syndrome, a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial was conducted.
      STUDY DESIGN: Healthy, premenopausal women between the ages of 18 and 45 years were recruited nationally across the United States at 12 outpatient centers and screened for moderate-to-severe, cyclically recurring premenstrual symptoms. Symptoms were prospectively documented over 2 menstrual cycles with a daily rating scale that had 17 core symptoms and 4 symptom factors (negative affect, water retention, food cravings, and pain). Participants were randomly assigned to receive 1200 mg of elemental calcium per day in the form of calcium carbonate or placebo for 3 menstrual cycles. Routine chemistry, complete blood cell count, and urinalysis were obtained on all participants. Daily documentation of symptoms, adverse effects, and compliance with medications were monitored. The primary outcome measure was the 17-parameter symptom complex score.
      RESULTS: Seven hundred twenty women were screened for this trial; 497 women were enrolled; 466 were valid for the efficacy analysis. There was no difference in age, weight, height, use of oral contraceptives, or menstrual cycle length between treatment groups. There were no differences between groups in the mean screening symptom complex score of the luteal (P = .659), menstrual (P = .818), or intermenstrual phase (P = .726) of the menstrual cycle. During the luteal phase of the treatment cycle, a significantly lower mean symptom complex score was observed in the calcium-treated group for both the second (P = .007) and third (P < .001) treatment cycles. By the third treatment cycle calcium effectively resulted in an overall 48% reduction in total symptom scores from baseline compared with a 30% reduction in placebo. All 4 symptom factors were significantly reduced by the third treatment cycle.
      CONCLUSIONS: Calcium supplementation is a simple and effective treatment in premenstrual syndrome, resulting in a major reduction in overall luteal phase symptoms. (Am J Obstet Gynecol 1998;179:444-52.)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reid R
        • Yen SSC.
        Premenstrual syndrome.
        Am J Obstet Gynecol. 1981; 139: 85-104
        • Freeman E
        • Rickels K
        • Sondheimer SJ
        • Polansky M.
        Ineffectiveness of progesterone suppository treatment for premenstrual syndrome.
        JAMA. 1990; 264: 349-353
        • Kendall K
        • Schnurr P.
        The effects of vitamin B6 supplementation on premenstrual symptoms.
        Obstet Gynecol. 1987; 70: 145-149
        • Casson P
        • Haln PM
        • Van Vugt DA
        • Reid RL.
        Lasting response to ovariectomy in severe intractable premenstrual syndrome.
        Am J Obstet Gynecol. 1990; 162: 99-105
        • Bancroft J
        • Boyle H
        • Warner Fraser HM.
        The use of LHRH agonist, buserelin, in the long term management of premenstrual syndrome.
        Clin Endocrinol. 1987; 26: 171-182
        • Watson NR
        • Studd JWW
        • Savvas M
        • Garnett T
        • Barber RJ.
        Treatment of severe premenstrual syndrome with oestradiol patches and cyclical norethistrone.
        Lancet. 1989; 2: 730-732
        • Wood SH
        • Mortola JF
        • Chan YF
        • Moossazadeh F
        • Yen SSC.
        Treatment of premenstrual syndrome with fluoxetine; a double-blind, placebo-controlled, crossover study.
        Am J Psychiatry. 1990; 147: 207-210
        • Thys-Jacobs S
        • Ceccarelli S
        • Bierman A
        • Weisman H
        • Cohen MA
        • Alvir J.
        Calcium supplementation in premenstrual syndrome: a randomized crossover trial.
        J Gen Intern Med. 1989; 4: 183-189
        • Penland JG
        • Johnson PE.
        Dietary calcium and manganese effects on menstrual cycle symptoms.
        Am J Obstet Gynecol. 1993; 168: 1417-1423
        • Lee SJ
        • Kanis JA.
        An association between osteoporosis and premenstrual and postmenstrual symptoms.
        Bone Miner. 1994; 24: 127-134
        • Thys-Jacobs S
        • Silverton M
        • Alvir J
        • Paddison P
        • Rico M
        • Goldsmith S.
        Reduced bone mass in women with premenstrual syndrome.
        J Womens Health. 1995; 4: 161-168
        • Thys-Jacobs S
        • Alvir J
        Calcium regulating hormones across the menstrual cycle—evidence of a secondary hyperparathyroidism in women with PMS.
        J Clin Endocrinol Metab. 1995; 80: 2227-2232
        • Thys-Jacobs S
        • Alvir J
        • Fratarcangelo P.
        Comparative analysis of three PMS assessment instruments: the identification of premenstrual syndrome with core symptoms.
        Psychopharmacol Bull. 1995; 31: 389-396
      1. Premenstrual syndrome: current findings and future directions. American Psychiatric Press, Washington1985: 88
        • Alvir JMA
        • Thys-Jacobs S.
        Premenstrual and menstrual symptom clusters and response to calcium treatment.
        Psychopharmacol Bull. 1991; 27: 145-148
        • Rubinow DR
        • Hoban MC
        • Grover GN
        • Galloway DS
        • Roy-Byrne P
        • Andersen R
        • et al.
        Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
        Am J Obstet Gynecol. 1988; 158: 5-11
        • Sundblad C
        • Modigh K
        • Andersch B
        • Erikson E.
        Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial.
        Acta Psychiatr Scand. 1992; 85: 39-47
        • Freeman E
        • Rickels K
        • Sondheimer S
        • Polansky M.
        A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome.
        JAMA. 1995; 274: 51-57
        • Steiner M
        • Steinberg S
        • Stewart D
        • et al.
        Fluoxetine in the treatment of premenstrual dysphoria.
        N Engl J Med. 1995; 332: 1529-1534
        • Menkes DB
        • Taghavi E
        • Mason PA
        • Spears GFS
        • Howard RC.
        Fluoxetine treatment of severe premenstrual syndrome.
        BMJ. 1992; 305: 346-347
        • Standing Committee on the Scientific Evaluation of Dietary Reference Intakes
        Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride.
        National Academy Press, Washington1997
        • Borer M
        • Bhanot V.
        Hyperparathyroidism: neuropsychiatric manifestations.
        Psychosomatics. 1985; 26: 597-601
        • Joburn C
        • Hetta J
        • Johansson H
        • Rastad J
        • Agren H
        • Akerstrom G
        • et al.
        Psychiatric morbidity in primary hyperparathyroidism.
        World J Surg. 1988; 12: 476-481
        • Rojansky N
        • Halbreich U
        • Zander K
        • Barkai A
        • Goldstein S.
        Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes.
        Gynecol Obstet Invest. 1991; 31: 146-152
        • Abraham GE
        • Lubran MM.
        Serum and red cell magnesium levels in patients with PMT.
        Am J Clin Nutr. 1981; 34: 2364-2366
        • Facchinetti F
        • Borella P
        • Sances G
        • Fioroni L
        • Nappi R
        • Genazzani A.
        Oral magnesium successfully relieves premenstrual mood changes.
        Obstet Gynecol. 1991; 78: 177-181